Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug
concentrations in blood to optimize pharmacotherapy. It considers the interindividual …

Abstract Treatment outcomes for major depressive disorder (MDD) need to be improved.
Presently, no clinically relevant tools have been established for stratifying subgroups or …

Conventional antidepressants are widely employed in several psychiatric and neurologic
disorders, yet the mechanisms underlying their delayed and partial therapeutic effects are …

Epigenetic processes, such as DNA methylation, and molecular chaperones, including
FK506-binding protein 51 (FKBP51), are independently implicated in stress-related mental …

Family, twin, and epidemiologic studies have suggested that both genes and environment
are important risk factors for the development of major depressive disorder (MDD). In the …

Introduction: Millions of people worldwide suffer from depression, but despite advances in
pharmacological therapies, many patients do not experience symptomatic remission or …

Depression is one of the most common mental disorders, predicted to be the leading cause
of disease burden by the next decade. There is great deal of emphasis on the central origin …

Background Adverse stress in early life negatively influences psychiatric health by
increasing the risk of developing depression and suicide in adulthood. Clinical …

Objective The aim of the current meta-analysis was to assess the influence of common
genetic polymorphisms in the 5-HTR2A gene on the efficacy of antidepressants in the …

Background: There is an ongoing search for biomarkers in psychiatry, for example, as
diagnostic tools or predictors of treatment response. The neurotrophic factor S100 calcium …